PSGL-1 was also identified as a potential RE target via genome-wide chromatin immunoprecipitation (ChIP)-sequencing experiments with Kasumi-1 cells and t (8;21)+ patient material. 31 In agreement ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and ...

PSGL-1 (P-selectin glycoprotein ligand-1) is an adhesion molecule that is involved in immune cell trafficking in response to tissue injury or inflammation. Verseau discovered that modulation of ...

Yuntao Wu, Professor, Molecular and Microbiology, School of Systems Biology, College of Science, is studying the structure of dicameric repeats (DR) of PSGL-1, a host protein that inhibits HIV ...

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody - Phase 1a/b Clinical Study of VTX-0811 in Solid Tumors Expected to ...

PSGL-1 VNTR polymorfism was related with site of thrombosis. AB and AC types were more frequent in patients with CVC-R and other vein thrombosis (p=0.02). Besides heterozygosity (AB+AC) relationship ...

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity, 2016; 44 (5): 1190 DOI: 10.1016/j.immuni.2016.04.015 ...

Proprietary PSGL-1 monoclonal antibodies induce tumor microenvironment activation, T-cell activation and naïve immune cell recruitment amounting to a coordinated immune attack on tumors.

PSGL-1, a novel target for immunotherapy, can induce macrophage reprogramming and activate a coordinated anti-tumor inflammatory response SHENYANG, China and BEDFORD Mass., Nov. 18, 2019 ...

By targeting PSGL-1, an adhesion molecule that is highly expressed on tumor-associated macrophages across most tumor types, VTX-0811 reprograms macrophages to a pro-inflammatory state, activates T ...